Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Extranodal NK/T-cell lymphomas~2. Confirmed pathological diagnosis by the Department of Pathology SGH/NUH/TTSH.~3. Age more than or equals to 21 years.~4. Stages IB or bulky disease, II - IV~5. ECOG performance 0-2~6. Laboratory tests: ANC more than or equals to 1000/mm3, platelet more than or equals to 75,000/mm3. Creatinine less than or equals to 2x ULN or creatinine clearance more than or equals to 50 ml/min; AST and ALT less than or equals to 3x ULN. Total bilirubin \< 1.5x ULN except \< 3x ULN in patients with Gilbert's (as defined as \> 80% unconjugated hyperbilirubinemia without other known cause); unless impairment is due to organ involvement by lymphoma.~7. Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria~1. Had prior systemic chemotherapy. Patients may be entered if they have had prior limited-field radiotherapy or a short course of glucocorticoids or single agent chemotherapy for an urgent local problem at diagnosis (e.g. epidural cord compression, superior vena caval syndrome).~2. History of peripheral neuropathy~3. HIV positive~4. Presence of CNS disease~5. Hypersensitivity to bortezomib, boron, or mannitol~6. Contraindication to any cytotoxic drug contained in the chemotherapy regimen.~7. Female subject of child-bearing potential not willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and one year beyond treatment completion.~8. Female subject pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotrophin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for women without child-bearing potential.~9. Invasive or active malignancy in past 2 years.~10. Serious concomitant medical illnesses that would jeopardize the patient's ability to receive the regimen with reasonable safety.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early stage (IB or bulky disease - II) (Type: EXPERIMENTAL): who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
- Advanced stage (III - IV) (Type: EXPERIMENTAL): will receive only chemotherapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).